TamifluĀ® saved lives during Swine Flu pandemic, international study finds

   
   
Tamiflu anti-viral medication
19 Mar 2014 00:01:00.000
PA 69/14

Patients hospitalised worldwide with Swine Flu during the 2009-10 pandemic were more likely to survive if they were treated with Tamiflu® and other similar anti-viral drugs, an international study led by academics at The University of Nottingham has found.

The research, published in The Lancet Respiratory Medicine, has shown that among adult patients infected with the H1N1 pandemic virus and subsequently admitted to hospital a 25 per cent reduction in the likelihood of death was seen if the patient had been treated with one of the anti-flu drugs known as neuraminidase inhibitors (NAIs) compared with no NAI treatment; by far the most commonly used drug was Tamiflu® (known to doctors as oseltamivir). When the data were analysed to look at early NAI treatment (within 48 hours of flu symptom onset) versus none, the risk of subsequent death was approximately halved. The study used data from more than 29,000 patients in 78 centres worldwide hospitalised with H1N1 during the 2009-10 pandemic and analysed the effect of treatment with NAIs on the likelihood of dying from the disease.

The results are the first to come out of the Post-Pandemic Review of Anti-Influenza Drug Effectiveness (PRIDE) study, jointly led by Professor Jonathan Van-Tam and Dr Puja Myles in the University’s Division of Epidemiology and Public Health.
Click here for full story

Taking out the guess work

Professor Van-Tam said: “There has been a lot of previous controversy about whether NAIs work in reducing serious complications and deaths due to influenza. Many countries stockpiled NAIs in readiness for a future pandemic. But it’s fair to say that when the 2009 pandemic actually started we did not know if these drugs would reduce deaths — governments around the world had simply made a best estimate that this would probably be so. 

"What we have now done is taken worldwide data from the 2009 pandemic itself, and analysed these to take an impartial view about the return we actually got on the investment made by so many governments. We did our best to assemble and combine all the data we could identify from around the entire globe and to perform the cleanest analysis possible, given the fact that it’s unethical to do clinical trials during a pandemic. From our results, it seems that in 2009, among patients hospitalised with the pandemic virus, the chances of dying could be reduced by roughly one half if an NAI was given with 48 hours of illness onset compared with no treatment. In my view, these data suggest that NAIs are a likely to be important in the fight against both seasonal and pandemic influenza.”

Fast action on flu

Interestingly, however, the study showed that the success of Tamiflu® appeared to be largely confined to the treatment of adult patients. The results found no significant reduction in deaths in children hospitalised with Swine Flu.

On the basis of the results, the authors are calling for NAI treatment to be used as soon as possible after the onset of symptoms in adults with suspected or confirmed influenza infection, especially those ill enough to be hospitalised.

The PRIDE Consortium, led by the Nottingham research team, is now working on further analyses to assess whether Tamiflu® prevented hospital admissions, pneumonia and admission to intensive care during the pandemic, the results of which are likely to be published by mid-2015.

A copy of the paper, Effectiveness of Neuraminidase Inhibitors in Reducing Mortality in Hospitalised Influenza A (H1N1) pdm09 Patients: An individual Participant Data Meta-Analysis, and comment can be viewed at www.thelancet.com/journals/lanres/onlinefirst  

— Ends —

Our academics can now be interviewed for broadcast via our new Globelynx fixed camera facility at the University. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email mediahub@nottingham.ac.uk or see the Globelynx website for how to register for this service.

For up to the minute media alerts follow us on Twitter

Notes to editors: The University of Nottinghamhas 43,000 students and is ‘the nearest Britain has to a truly global university, with campuses in China and Malaysia modelled on a headquarters that is among the most attractive in Britain’ (Times Good University Guide 2014). It is also the most popular university among graduate employers, the world’s greenest university, and winner of the Times Higher Education Award for ‘Outstanding Contribution to Sustainable Development’. It is ranked in the World's Top 75 universities by the QS World University Rankings.

Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…



Story credits

More information is available from Professor Jonathan Van Tam or Dr Puja Myles via Emma Thorne, Media Relations Manager, in the Communications Office at The University of Nottingham, on +44 (0)115 951 5793, emma.thorne@nottingham.ac.uk
 

Emma Thorne Emma Thorne - Media Relations Manager

Email: emma.thorne@nottingham.ac.uk Phone: +44 (0)115 951 5793 Location: University Park

Additional resources

No additional resources for this article

Related articles

Flu, 50% of at risk patients are still not vaccinated

Published Date
Saturday 1st February 2014

Volunteers needed for swine flu research

Published Date
Wednesday 28th October 2009

Preparing for the next large-scale flu outbreak

Published Date
Wednesday 16th December 2009

How is influenza transmitted between people?

Published Date
Tuesday 22nd January 2013

Media Relations - External Relations

The University of Nottingham
C Floor, Pope Building (Room C4)
University Park
Nottingham, NG7 2RD

telephone: +44 (0) 115 951 5798
email: communications@nottingham.ac.uk